Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831

Our objective was to validate the NSABP 8-gene trastuzumab-benefit signature, developed and initially validated in NRG Oncology/NSABP B-31 in Alliance/NCCTG N9831. The B-31 and N9831 trials demonstrated the benefit of adding trastuzumab to chemotherapy in the adjuvant setting for HER2+ breast cancer...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JNCI Cancer Spectr
Main Authors: Pogue-Geile, Katherine L, Song, Nan, Serie, Daniel J, Wang, Ying, Gavin, Patrick G, Kim, Rim S, Tanaka, Noriko, Fumagalli, Debora, Taniyama, Yusuke, Li, Zhuo, Rastogi, Priya, Swain, Sandra M, Mamounas, Eleftherios P, Geyer, Charles E, Wolmark, Norman, Lucas, Peter C, Paik, Soonmyung, Thompson, E Aubrey
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Brief Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7674704/
https://ncbi.nlm.nih.gov/pubmed/33241186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jncics/pkaa058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados